Kristina W. Thiel

Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.

Therapeutic applications of DNA and RNA aptamers.

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Progesterone: the ultimate endometrial tumor suppressor.

Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.

Endometrial cancer: reviving progesterone therapy in the molecular age.

Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.

Endometrial cancer.

An exploratory study of the variables impacting preterm birth rates in New Mexico.

Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer.

Epigenetic modification restores functional PR expression in endometrial cancer cells.

Drug resistance mediated by AEG-1/MTDH/LYRIC.

The consequence of oncomorphic TP53 mutations in ovarian cancer.

The epidermal growth factor receptor and its ligands in cardiovascular disease.

The estrogen receptor joins other cancer biomarkers as a predictor of outcome.

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.

Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Past, present, and future of hormonal therapy in recurrent endometrial cancer.

Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.

Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Genetic Deficiency of Mtdh Gene in Mice Causes Male Infertility via Impaired Spermatogenesis and Alterations in the Expression of Small Non-coding RNAs.

miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer.

NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.

Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.

Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.

Prediction of chemo-response in serous ovarian cancer.

Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology.

High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Role of metadherin in estrogen-regulated gene expression.

Synthetically lethal nanoparticles for treatment of endometrial cancer.

AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.

A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables.

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.

An integrated prediction model of recurrence in endometrial endometrioid cancers.

MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.

Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling.

Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

The Dawning of the Age of Personalized Medicine in Gynecologic Oncology.

Genomic characterization of five commonly used endometrial cancer cell lines.

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

Creation and validation of models to predict response to primary treatment in serous ovarian cancer.

Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome.

Targeting Wnt Signaling in Endometrial Cancer.

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy.

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer.

Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line.

Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets.

Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer.

AptamerRunner: An accessible aptamer structure prediction and clustering algorithm for visualization of selected aptamers.